| Description | B220, an antiviral agent, inhibits the growth of HSV-1, HSV-2, and human cytomegalovirus (CMV). |
| In vitro | B220抑制中性粒细胞释放活性氧物质以及其细胞内活性氧物质的生成。这种抑制不是通过B220直接清除氧自由基的活动来实现的，并且B220对组装好的氧化酶活性没有即时影响。B220减少了中性粒细胞吞噬荧光标记的包裹酵母细胞的能力。预先与B220（10 µg/mL）孵育的细胞，接着用甲酰化肽fMLP刺激，其表面C3受体的动员少于对照细胞[2]。 |
| molecular weight | 318.42 |
| Molecular formula | C20H22N4 |
| CAS | 112228-65-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 9 mg/mL (28.26 mM), Sonication is recommended. |
| References | 1. Mohammed Homman, et al. Pharmaceutical formulation of B220 for topical treatment of herpes. EP 2489354 A1. 2. Harbecke O, et al. The synthetic non-toxic drug 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline inhibits neutrophil production of reactive oxygen species. J Leukoc Biol. 1999 Jun;65(6):771-7. |